| Literature DB >> 30961261 |
Abstract
Gold nanoparticles are widely used in biomedical applications. Their ease of surface modification, biocompatibility and the presence of surface plasmons makes them ideal tools for a variety of investigations. Polyelectrolyte-coated gold nanoparticles are employed in areas such as imaging, drug delivery and gene therapy; however, it is not well understood how different factors such as the polyelectrolyte and salt concentration affect the coating on the nanoparticles and hence their performance. Here, these parameters were systematically varied and their effect on the stability of the colloidal nanoparticle suspension was monitored. An increase in the polyelectrolyte concentration from 0 to 30 mg/mL led to a red shift of the surface plasmon peak and an increase in the zeta potential. Concentrations between 5 mg/mL and 30 mg/mL resulted in the most stable systems, with 1 mg/mL being the most unstable. Stable nanoparticle suspensions were formed in salt concentrations below 50 mM, while higher concentrations caused colloidal instability and irreversible aggregation.Entities:
Keywords: biomedical; gold; gold nanoparticles; polyelectrolyte; stability
Year: 2018 PMID: 30961261 PMCID: PMC6402027 DOI: 10.3390/polym10121336
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Figure 1Layer-by-layer (Lbl) attachment of polydiallyldimethylammonium chloride (PDADMAC) onto citrate-capped gold nanoparticles.
Figure 2(A) UV–vis spectra of PDADMAC coated AuNP at concentrations of 0–30 mg/mL PDADMAC in 1 mM NaCl. (B) Zeta potential measurements as a function of PDADMAC concentration at pH 6.0.
Concentrations of PDADMAC showing polyelectrolyte chains to nanoparticles (PC/NP) ratio, compared to their average surface plasmon resonance (SPR) peak position and zeta potentials at pH 6.0 ± 0.3.
| PDADMAC Concentration (mg/mL) | PC/NP Ratio | SPR Maximum Absorbance Peak (nm) | Absorbance (a.u.) | Zeta Potential (mV) |
|---|---|---|---|---|
| 0 | 0 | 513 ± 0.3 | 0.48 ± 0.2 | −9.6 ± 8.9 |
| 0.1 | 21.5 | - * | - * | 0.3 ± 3.7 |
| 1.0 | 215 | 537 ± 1.5 | 0.10 ± 0.09 | 5.7 ± 14 |
| 5.0 | 1075 | 539 ± 0.47 | 0.58 ± 0.04 | 35 ± 8.9 |
| 10 | 2150 | 540 ± 2.5 | 0.45 ± 0.07 | 39 ± 9.1 |
| 30 | 6450 | 542 ± 0.94 | 0.51 ± 0.08 | 48 ± 7.9 |
* Fully aggregated and was unable to be removed from the centrifuge tubes with a concentration of AuNP suitable for ultraviolet-visible (UV–Vis) spectroscopy.
The average SPR peak and absorbance as determined by UV–vis spectroscopy for 5 mg/mL PDADAMAC-coated AuNP.
| Salt Concentration (M) | Average SPR Peak (nm) | Average Absorbance (a.u.) |
|---|---|---|
| 0 | 543 ± 1.2 | 0.69 ± 0.04 |
| 0.001 | 539 ± 0.47 | 0.58 ± 0.04 |
| 0.05 | 540 ± 3.7 | 0.17 ± 0.05 |
| 0.1 | * | * |
| 0.5 | * | * |
* At 0.1 M and 0.5 M, the sample irreversibly aggregated and was unable to be removed from the centrifuge tubes with a concentration of AuNP suitable for UV–vis spectroscopy.
Figure 3UV–vis spectra of varying salt concentrations of 5 mg/mL PDADMAC on 5 nm AuNPs.